DDInter71 DDInter1628
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) resembles {v} (Compound) Benzocaine
Benzocaine {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is regulated by {v} (Gene) CBLL1
CBLL1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) FAM57A
FAM57A {u} (Gene) is regulated by {v} (Gene) TMEM5
TMEM5 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is regulated by {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Dolutegravir {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) regulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Aminoglutethimide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Aminoglutethimide (Compound) resembles Benzocaine (Compound) and Benzocaine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ruxolitinib (Compound)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is regulated by CBLL1 (Gene) and CBLL1 (Gene) is upregulated by Ruxolitinib (Compound)
Aminoglutethimide (Compound) downregulates FAM57A (Gene) and FAM57A (Gene) is regulated by TMEM5 (Gene) and TMEM5 (Gene) is downregulated by Ruxolitinib (Compound)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is regulated by JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Ruxolitinib (Compound)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ruxolitinib (Compound)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Ruxolitinib (Compound)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) regulates KLHDC2 (Gene) and KLHDC2 (Gene) is downregulated by Ruxolitinib (Compound)